AGM
AMLX icon

Alpine Global Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Alpine Global Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,034
Closed -$90.8K – 140
2024
Q4 		$90.8K Buy
+24,034
New +$113K 0.01% 189
2024
Q3 		– Sell
-108,862
Closed -$207K – 172
2024
Q2 		$207K Buy
+108,862
New +$211K 0.04% 304

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alpine Global Management's AMLX Position: Q1 2025 in Review

Alpine Global Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 24,034 shares — an estimated $90.8K sold.

Alpine Global Management first reported a position in AMLX in Q2 2024 and held it in 2 quarters. The position peaked at $207K in Q2 2024. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

  • Alpine Global Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Alpine Global Management sold 24,034 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $90.8K.
  • Alpine Global Management first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Alpine Global Management's Amylyx Pharmaceuticals position peaked at $207K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.